SCHEMBL188183

SCHEMBL188183

O=[N+]([O-])c1cccc(Br)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.38
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 4/20 0.37
ALDH1A1 P00352 7/20 0.36
PDE10A Q9Y233 1/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
CYP1A2 P05177 3/20 0.36
MEN1 O00255 2/20 0.36
CYP3A4 P08684 2/20 0.36
NOS1 P29475 2/20 0.36
CYP2C19 P33261 2/20 0.36
NOS2 P35228 2/20 0.36
BLM P54132 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
GPR35 Q9HC97 1/20 0.35
NQO2 P16083 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31511551 1.00 TSHR (0.38) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL3294386 0.84 TSHR (0.46) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL3144065 0.77 LMNA (0.41) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL18387601 0.74 LMNA (0.38) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL16289365 0.74 LMNA (0.38) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL873623 0.74 TSHR (0.43) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL31052632 0.74 NOS3 (0.41) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL4494414 0.74 LMNA (0.38) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL3865531 0.74 GPR35 (0.45) TSHRLMNATDP1ALDH1A1PDE10A
SCHEMBL30945318 0.74 ALDH1A1 (0.49) TSHRLMNATDP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104478862-A New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits ASTRAZENECA AB 2015-04-01 CN claimed
CN-104447710-A COMPOUNDS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS ASTRAZENECA AB 2015-03-25 CN claimed
CN-101768036-B Method for preparing aryl-substituted nitrogen heteroaromatic ring compound in alcohol solvent UNIV DALIAN TECH 2013-05-08 CN claimed
CN-101768036-A Method for preparing aryl-substituted nitrogen heteroaromatic ring compound in alcohol solvent UNIV DALIAN TECH 2010-07-07 CN claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
CN-115650982-B Compounds for imaging TAU protein aggregates AC免疫有限公司 2026-05-19 CN disclosed
US-12552777-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2026-02-17 US disclosed
EP-4676923-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS Cancer Research Technology Limited (GB) 2026-01-14 EP disclosed
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI), INC. (CN) 2025-07-10 US disclosed
WO-2025094117-A1 SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF GT GAIN THERAPEUTICS SA (CH) 2025-05-08 WO disclosed
CN-119874700-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-04-25 CN disclosed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
WO-2012117069-A1 RADIOFLUORINATION METHOD GE HEALTHCARE LIMITED (GB) 2012-09-07 WO disclosed
WO-2012093101-A1 INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) NOVARTIS AG (CH) 2012-07-12 WO disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
EP-2401281-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-01-04 EP disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
CN-101768036-A Method for preparing aryl-substituted nitrogen heteroaromatic ring compound in alcohol solvent UNIV DALIAN TECH 2010-07-07 CN disclosed
WO-2004004715-A2 NOVEL DELTA OPIOID RECEPTOR LIGANDS GLAXOSMITHKLINE SPA (IT) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552777-B2 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof AIFM1, BAD, IRAK1 TSHR 1582/4885LMNA 930/4885TDP1 339/4885
US-20250221988-A1 COMPOUNDS AND METHODS OF TREATING CANCERS GSPT1, GSS, G6PC1 TSHR 1879/4885LMNA 3243/4885TDP1 267/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK TSHR 1156/4885LMNA 4499/4885TDP1 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.